Minimal residual disease–directed therapy in acute myeloid leukemia

Minimal residual disease quantitation in acute myeloid leukemia.

The prognosis for patients with acute myeloid leukemia (AML) is heterogeneous. A minority of patients have clinical and biologic features associated with a very high risk of relapse. For the remaining patients, no clear prognostic factors can be identified at diagnosis. The degree of treatment response is likely to be an informative predictor of outcome for these patients. Modern assays to dete...

Detection of minimal residual disease in acute myeloid leukemia.

Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patien...

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

We used flow cytometry to quantify minimal residual disease (MRD) in 56 patients with acute myeloid leukemia (AML) expressing a leukemia-associated phenotype. Thirty-four patients aged 18 to 60 years were entered into the AML-10 protocol (induction, consolidation, and autologous stem-cell transplantation [ASCT]), whereas 22 patients older than 60 years received the AML-13 protocol (induction, c...

Evidence-Based Focused Review Minimal residual disease–directed therapy in acute myeloid leukemia

Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; Department of Medical and Molecular Genetics, King’s College London, Faculty of Life Sciences and Medicine, London, United Kingdom; Buffalo Medical Group, Buffalo, NY; Clinical Research Division, Fred Hutchinson Cancer Research...

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.